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Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers with a 5-year
survival rate of less than 5%. Moreover, PDAC escapes early detection and resists treat-
ment. Multiple combinations of genetic alterations are known to occur in PDAC including
mutational activation of KRAS, inactivation of p16/CDKN2A and SMAD4 (DPC4) and dysreg-
ulation of PTEN/PI3K/AKT signaling. Through their interaction with Wingless-INT pathway,
the downstream molecules of these pathways have been implicated in the promotion
of epithelial–mesenchymal transition (EMT). Emerging evidence has demonstrated that
cancer stem cells (CSCs), small populations of which have been identiﬁed in PDAC, and
EMT-type cells play critical roles in drug resistance, invasion, and metastasis in pancreatic
cancer. EMT may be histologically represented by the presence of tumor budding which is
described as the occurrence of single tumor cells or small clusters (<5) of dedifferentiated
cells at the invasive front of gastrointestinal (including colorectal, oesophageal, gastric, and
ampullary) carcinomas and is linked to poor prognosis. Tumor budding has recently been
shown to occur frequently in PDAC and to be associated with adverse clinicopathologi-
cal features and decreased disease-free and overall survival. The aim of this review is to
present a short overview on the morphological and molecular aspects that underline the
relationship between tumor budding cells, CSCs, and EMT-type cells in PDAC.
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GENERAL OVERVIEW
Pancreatic ductal adenocarcinoma (PDAC) is a common cause of
cancer death and has a very poor prognosis (Hidalgo, 2010). Most
patients present with advanced stage disease and have a median
survival of less than 1 year (Stathis and Moore, 2010). Surgical
resection is the only potentially curative treatment of PDAC. Clas-
sical histomorphological features like tumor size, blood vessel or
lymphatic invasion and presence of lymph node metastases con-
stitute essential prognostic determinants in pancreatic cancer and
are invariably included in the pathology reports, with tumor stage
being the most important of all (Fernandez-del-Castillo et al.,
2012). The lethal nature of PDAC has been attributed to the
propensity of PDAC cells to rapidly disseminate to the lymphatic
system and distant organs (Li et al., 2012).
However, even patients with completely resected, node-
negative PDACs eventually die of their disease.Within this context
and considering the fact that the management of PDAC remains
suboptimal and that adjuvant therapy has resulted to limited
progress, the identiﬁcation of additional reliable and reproducible
prognostic markers that would enable better patient stratiﬁca-
tion and eventually provide a guide towards a more successful
and individualized therapy, is mandatory (Welsch et al., 2007;
Hidalgo, 2010).
MOLECULAR CHARACTERISTICS OF PANCREATIC CANCER
Multiple combinations of genetic alterations are known to occur
in PDAC including mutational activation of oncogenes like KRAS
(>90% of PDACs), inactivation of tumor suppressor genes like
TP53 (75–85%), p16/CDKN2A (40%), and SMAD4 (DPC4; 60%)
and dysregulation of PTEN/PI3K/AKT signaling (Hruban et al.,
2012). Especially the transforming growth factor-beta (TGF-β)
is an important and commonly deregulated signaling pathway in
pancreatic carcinomas. Alteration of this pathway has a prominent
function in both the tumor cell and stromal cell compartments
(McCleary et al., 2012). SMAD4 inactivation is present in more
than half of all pancreatic tumors, and this phenomenon appears
to be speciﬁc for pancreatic adenocarcinoma (Schutte et al., 1996;
Wilentz et al., 2000). Through a functional TGF-β signaling path-
way and the presence of activating KRAS mutations, TGF-β
ligand stimulation promotes tumor cells to undergo epithelial–
mesenchymal transition (EMT) and thus develop an aggressive
and invasive phenotype (Ellenrieder et al., 2001).
EPITHELIAL–MESENCHYMAL TRANSITION (EMT)
Epithelial–mesenchymal transition is a biologic process essential
for embryonic processes like gastrulation and reﬂects a reversible
embryonic program, which is considered a critical feature of
normal development and allows partial or complete transition
between an epithelial and amesenchymal phenotype. If aberrantly
activated acts as a trigger of tumor progression and metasta-
sis (Kalluri, 2009; Thiery et al., 2009). During EMT epithelial
cells undergo morphologic changes characterized by a transi-
tion from an epithelial to a mesenchymal phenotype, leading to
increased migratory capacity and invasiveness (Karamitopoulou
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et al., 2011). The hallmark of EMT is the down-regulation of the
cell adhesion molecule E-cadherin, which is a transmembrane
protein essential for the stable adherens junctions, and the up-
regulation of the mesenchymal molecules vimentin, ﬁbronectin,
and/or N-cadherin. It has been reported that repression of E-
cadherin is associated with dedifferentiation, inﬁltrative growth,
and high incidence of lymph nodemetastasis in pancreatic cancer,
as well as various other malignancies (Hase et al., 1993; Tanaka
et al., 2003; Schmalhofer et al., 2009). In more details, EMT is
activated by key signaling pathways, including the TGF-β path-
way, converging in the stimulation of EMT activators, a group of
transcription factors repressing epithelial gene expression. These
includemembers of the snail family, of the bHLH family and of the
zinc ﬁnger homeodomain (ZFH) family (ZEB1 and ZEB2; Thiery
et al., 2009). In many cancers, including pancreatic cancer, EMT
has been shown to correlatewith high-grademalignancy including
the competence to form metastasis (Krantz et al., 2012).
Epithelial–mesenchymal transition occurs at the invasive front
of cancers and is essentially reversible by a process called
mesenchymal-to-epithelial transition (MET; Thiery and Slee-
man, 2006; Wu and Zhou, 2009). In pancreatic cancer, it was
shown to be an independent indicator of poor prognosis (Masugi
et al., 2010).
Epithelial–mesenchymal transition activators not only activate
cellular motility, but are also associated with the maintenance of
stem cell properties and cell survival (Mani et al., 2008;Morel et al.,
2008). Moreover, EMT has been linked to cellular self-renewal
programs of cancer stem cells (CSCs) and apoptosis resistance,
which are also features of therapy resistance (Krantz et al., 2012).
CANCER STEM CELLS
Cancer stem cells are deﬁned by their immortality, their capacity to
reproduce all derived cell phenotypes of a cancer and by biological
and biochemical markers such as CD44, CD133, aldehyde, dehy-
drogenase, etc. Stemcell populations have been identiﬁed inPDAC
representing less than 1% of the total (Floor et al., 2011). These
cells show a triple positive phenotype for CD44/CD24/EpCAM
and are 100-fold more tumorigenic than the other neoplastic cells
(Floor et al., 2011). Recently, in vitro studies have suggested that
CSCs andEMT-type phenotypes overlap and that the properties of
CSCs and EMT-type cells may be linked through sharedmolecular
features (Floor et al., 2011).
TUMOR BUDDING IN PDAC
Tumor budding corresponds to a type of diffusely inﬁltrative
growth observed in many gastrointestinal cancers (including
oesophageal, gastric, colorectal, and ampullary cancers) and is
deﬁned as the presence of detached isolated single cells or small
cell clusters (up to ﬁve cells) scattered in the stroma at the inva-
sive tumor margin (Prall, 2007). The identiﬁcation of tumor
budding is highly facilitated by immunostaining with cytoker-
atin which helps to better recognize and visualize the buds. Aim
of the tumor buds seems to be the degradation of the peritu-
moral connective tissue, the evasion of host’s response and ﬁnally
the invasion of the lymphatic and blood vessels with the con-
sequence of local and distant metastasis (Lugli et al., 2012a). To
achieve this aim tumor buds have to detach themselves from the
main tumor body by loss of membranous expression of the adhe-
sion molecule E-cadherin. Indeed, aggressive, dissociated tumor
buds not only lose membranous E-cadherin, but also express
ﬁbronectin within the cytoplasm implying a more mesenchymal
phenotype underlining the interaction between tumor buds and
the surrounding stroma (Kirchner and Brabletz, 2000). Moreover,
tumor budding cells have been shown to express nuclear β -catenin
which implicates the Wingless-INT (WNT) signaling pathway
in the process of tumor budding (Karamitopoulou et al., 2011).
This is further underlined by expression of laminin-5γ2 which is
supposed to lead to activation of SLUG and ZEB1 (Schmalhofer
et al., 2009).
In a recent study by our own group the presence and prog-
nostic signiﬁcance of tumor budding in PDAC were investigated
(Karamitopoulou et al., 2012). We found an association between
high-grade budding and aggressive clinicopathological features of
the tumors, like advanced pT-stage and the presence of lymphatic
invasion. Furthermore, we could show that tumor budding occurs
frequently in pancreatic cancer and is a strong and independent
prognostic factor that can be used as an indicator of patient out-
come having a more powerful prognostic ability than other more
classic prognostic factors including TNM (Tumor, Node,Metasta-
sis) stage. In more detail, high-grade tumor budding was strongly
associatedwith less overall and disease-free survival, while patients
with low-grade budding survived longer and had longer disease-
free intervals independently of the presence of other adverse
prognostic factors like lymphatic invasion, presence of lymphnode
metastasis or positive resection margins (Figures 1A,B).
CSCs, EMT-CELLS, BUDDING-CELLS, AND CELL
PROLIFERATION
Although cancer cells are often considered as highly proliferative,
there is less proliferation at the invasion front of carcinomas (Jung
et al., 2001; Carmeliet et al., 2009). Moreover, cells undergoing
EMT, just as cells during embryonic development, stop divid-
ing when migrating. A likely explanation is that the cytoskeletal
changes occurring during EMT are incompatible with cell divi-
sion (Barrallo-Gimeno and Nieto, 2005; Richardson et al., 2006;
Carmeliet et al., 2009; Giampieri et al., 2009). In support of this,
Ki67 labeling was found to be decreased at the invasion front
of tumors (Friedl and Gilmour, 2009). Moreover, a transcrip-
tion factor, inducing EMT and SNAIL was also shown to induce
cell cycle inhibitor p21, repress cell cycle activator cyclin D and
induce resistance to apoptosis (Kajita et al., 2004; Vega et al., 2004;
Perez-Losada et al., 2005). In a breast cancer cell line down-
regulation of cyclin A1 was shown to increase migration and
decrease proliferation (Lehn et al., 2010).
The relation of CSC- and EMT-properties with cell prolifera-
tion is not obvious. Indeed, typical EMT-cells do not proliferate.
If CSCs represent dormant cells that proliferate slowly, thus escap-
ing chemotherapy, this is compatible with cells in EMT state (Sell,
2006). If on the other hand, CSCs represent the most aggressive,
highly proliferating neoplastic cells, this could be incompatible
with EMT state (Yeung et al., 2010). However, the overlap of CSC-
and EMT-properties with proliferative activity has not necessarily
to be simultaneous. If we assume that the EMT state represents a
transient phase in the lifetime of a neoplastic cell, it is likely that
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FIGURE 1 | Low- (A) and high-grade (B) tumor budding in PDAC (pancytokeratin staining, ×400). Arrows indicate examples of tumor budding.
the most competitive tumor cells when detached from the oth-
ers (i.e., tumor budding cells) adopt transiently an EMT state that
allows them to invade andmetastasize and then, when in their new
site, they recover their previous highly aggressive and proliferat-
ing nature. In this case, some biomarkers of CSCs or EMT-cells
would be expressed only at certain stages of this process (Floor
et al., 2011).
Interestingly, in keeping with the previous assumption, in a
recent work by our group performed in colorectal cancer, tumor
budding cells were shown to have reduced proliferative acti-
vity as measured by Ki67, compared with the main tumor (Lugli
et al., 2012b).
CONCLUSION
Tumor budding is thought to reﬂect the process of EMT which
allows neoplastic epithelial cells to acquire a mesenchymal phe-
notype thus increasing their capacity for migration and invasion
and help them become resistant to apoptotic signals (Guarino
et al., 2007; Katoh, 2011). Additionally, it has been suggested that
tumor budding cell may have a “stem cell” character. Possible
interactions of tumor budding cells, EMT-type cells, and CSCs
are shown in Figure 2. The WNT pathway which is involved in
the process of tumor budding has a strong association with CSCs
and the development of a stem cell-like phenotype (Katoh, 2011).
Moreover, emerging evidence has shown that CSCs share similar
FIGURE 2 | Possible interactions of tumor budding cells, EMT-type cells, and CSCs.
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molecular characteristics with EMT-type cells, are drug resistant
and have higher metastatic potential (Mani et al., 2008; Morel
et al., 2008). In an excellent recent work by Floor et al. (2011)
similarities between CSCs and EMT-cells were further explored.
It was shown that cancer cells in EMT, that is, EMT-cells, share
many properties with the classical so-called “CSC”s. In fact, there
are many indications that CSCs present characteristics of EMT-
cells and conversely that EMT-cells acquire properties of CSCs,
including expression of the markers CD44/CD24, dormancy
etc., and vice-versa. The overlap of CSC- and EMT-properties
has been also extensively discussed in many recent publications
(Alexander et al., 2008; Tomaskovic-Crook et al., 2009; Singh and
Settleman, 2010).
However, there is still controversy regarding the relationship
between tumor budding cells, EMT-type cells, and CSCs. Charac-
terization studies of the tumor budding cells are very few and so
far restricted to immunohistochemical ﬁndings. To date it has
not been attempted to characterize tumor budding cell at the
molecular level. In a previous immunohistochemical study on col-
orectal cancer from the several potential CSC markers (ABCG5,
ALDH1, CD24, CD44, CD90, CD133, EpCam) that have been
proposed for solid tumors, only ABCG5 expression in tumor
budding cell was found to be associated with poor survival of
the patients (Ellenrieder et al., 2001; Visvader and Lindeman,
2008). Further characterization of the tumor budding cells in
PDAC on a protein and gene level, especially concerning genes
and gene products of the TGF-β and WNT signaling pathways
which are promoting EMT- and CSC-features, as well as more
detailed exploration of the possible phenotypical and molecular
similarities between budding cells, EMT-type cells, and CSCs are
needed. Creating a molecular “tumor budding promoting pro-
ﬁle” would help to better stratify PDAC patients into prognostic
subgroups and to develop possible targets for an individualized
therapy.
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